β2 déjà vu

Chest

Volumn 129, Issue 1, 2006, Pages 3-5

  O'Byrne, Paul M ^a,b,c   Ädelroth, Ellinor ^a,d  

^a St Joseph's Hospital ^*

^b ST JOSEPH S HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; ISOPRENALINE; SALBUTAMOL; SALMETEROL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE;

AFRICAN AMERICAN; AIRWAY OBSTRUCTION; ASTHMA; AUSTRALIA; BRONCHODILATATION; BRONCHOSPASM; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MORTALITY; NEW ZEALAND; PRIORITY JOURNAL; SYMPTOMATOLOGY; UNITED KINGDOM; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; INHALATIONAL DRUG ADMINISTRATION; NOTE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; BRONCHOCONSTRICTION; HUMANS; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME;

EID: 33144462781     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.1.3     Document Type: Editorial

References (13)

1. Speizer FE, Doll R, Heaf DP, et al. Investigation into the use of drugs proceeding death from asthma. BMJ 1968; 1:229-243
2. Stolley PD. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972; 105:883-890
3. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1:917-922
4. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-506
5. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26
6. Castle W, Fuller RW, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037
7. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411
8. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397
9. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and 1 reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136
10. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170:836-844
11. Wolfe J, LaForce C, Sokol W, et al. Formoteral, 24 μg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 2006; 129:27-38
12. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 1994; 7:914-920
13. National Institutes of Health. Global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health, 2004; NIH Publication No. 02-3659